A surprise rejection is weighing on Sarepta's shares today.
Novavax's RSV vaccine may not be dead after all.
The FDA will hold an advisory committee meeting after all.
Its high-profile DMD gene-therapy candidate hit an unexpected stumbling block.
Catalyst's shares took a sizable hit this morning.
Glaukos makes a bid for Avedro in an all-stock transaction.
Canopy Growth, Charlotte's Web Holdings, and HEXO Corp. are worth checking out this month. Here's why.
These five-star medicines should continue to push the industry higher in the next decade, despite the political blowback surrounding U.S. prescription drug prices.
Aphria appears to have turned a corner.
The small-cap healthcare stocks Catalyst Pharmaceuticals and MedMen Enterprises have enormous upside potential.
Auxly Cannabis Group and Charlotte's Web Holdings are poised for serious growth.
These blue-chip biotechs delivered mixed reports Tuesday.
The biopharma is gearing up for Vascepa's highly-anticipated label expansion.
Adverum Biotechnologies and Catalyst Pharmaceuticals could both post sizable gains next month.
These three biotech stocks might be outstanding buys right now.
The pharmaceutical giant will reportedly combine its legacy products business with generic drug major Mylan.
The marijuana stock bubble may have burst, but opportunity still abounds for long-term investors.
Acadia Pharmaceuticals and Dynavax Technologies are having a rough week.
OrganiGram is one of the cheapest Canadian pot stocks right now.
PetMed's weaker-than-expected fiscal first quarter isn't sitting well with shareholders this morning.